PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02572206|
Recruitment Status : Terminated (NIMH terminated study)
First Posted : October 8, 2015
Last Update Posted : September 28, 2016
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Radiation: PET/SPECT Scan Device: MRI scan||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers|
|Study Start Date :||September 2015|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||June 2016|
PET/SPECT and MRI scans
PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.
30 minute structural MRI will be obtained to permit co-registration of PET images.
Radiation: PET/SPECT Scan
PET scan will be performed on a mCT scanner.
Other Name: PET
Device: MRI scan
Structural MRI will be obtained to permit co-registration of PET images.
Other Name: MRI
- Level of MGluR5 PET binding in dorsolateral prefrontal cortex (DLPFC) in CNTNAP mutation carriers vs comparison subjects [ Time Frame: 90 minutes and the comparison will be binding in the specific regions listed (e.g., dorsolateral prefrontal cortex) controlled by binding in the cerebellum/input function. ]Evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.
- Level of mGluR5 PET binding in hippocampus and primary visual cortex (occipial pole) [ Time Frame: 90 minutes and the comparison will be binding in the specific regions listed controlled by binding in the cerebellum/input function. ]Evaluate PET mGluR5 binding in other regions of potential relevance, including hippocampus and primary visual cortex in order to determine ideal regions of interest for future intervention studies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02572206
|United States, New York|
|New York State Psychiatric Insitute|
|New York, New York, United States, 10032|
|Principal Investigator:||Jeffrey A Lieberman, MD||New York State Psychiatric Institute|